Puesta al día en la candidiasis invasora en el paciente crítico no neutropénico

Aguado, 2011, Recomendaciones sobre el tratamiento de la candidiasis invasiva y otras infecciones por levaduras de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2011, Enferm Infecc Microbiol Clin., 29, 345, 10.1016/j.eimc.2011.01.008 Aguilar, 2014, Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration, J Antimicrob Chemother., 69, 1620, 10.1093/jac/dkt542 Almirante, 2005, Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003, J Clin Microbiol., 43, 1829, 10.1128/JCM.43.4.1829-1835.2005 Andes, 2012, Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials, Clin Infect Dis., 54, 1110, 10.1093/cid/cis021 Arendrup, 2011, National surveillance of fungemia in Denmark (2004 to 2009), J Clin Microbiol., 49, 325, 10.1128/JCM.01811-10 Asmundsdottir, 2013, Nationwide study of candidemia, antifungal use, and antifungal drug resistance in Iceland, 2000 to 2011, J Clin Microbiol., 51, 841, 10.1128/JCM.02566-12 Asmundsdottir, 2008, Molecular epidemiology of candidemia: evidence of clusters of smoldering nosocomial infections, Clin Infect Dis., 47, e17, 10.1086/589298 Barchiesi, 2004, Outbreak of fungemia due to Candida parapsilosis in a pediatric oncology unit, Diagn Microbiol Infect Dis., 49, 269, 10.1016/j.diagmicrobio.2004.03.011 Bassetti, 2015, Are prophylactic antifungals in highly colonized patients safe and effective?, Intensive Care Med., 41, 1336, 10.1007/s00134-015-3888-9 Bassetti, 2014, A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality, Intensive Care Med., 40, 839, 10.1007/s00134-014-3310-z Berenguer, 1993, Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection, Diagn Microbiol Infect Dis., 17, 103, 10.1016/0732-8893(93)90020-8 Cleveland, 2012, Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011, Clin Infect Dis., 55, 1352, 10.1093/cid/cis697 Colombo, 2006, Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers, J Clin Microbiol., 44, 2816, 10.1128/JCM.00773-06 Cornely, 2012, ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients, Clin Microbiol Infect., 18, 19, 10.1111/1469-0691.12039 Dimopoulos, 2012, Efficacy and safety of anidulafungin in elderly, critically ill patients with invasive Candida infections: a post hoc analysis, Int J Antimicrob Agents., 40, 521, 10.1016/j.ijantimicag.2012.07.018 Dizbay, 2008, Molecular investigation of a fungemia outbreak due to Candida parapsilosis in an intensive care unit, Braz J Infect Dis., 12, 395, 10.1590/S1413-86702008000500010 Fernández-Ruiz, 2014, Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis, Clin Infect Dis., 58, 1413, 10.1093/cid/ciu158 Fridkin, 2005, Candidemia is costly-plain and simple, Clin Infect Dis., 41, 1240, 10.1086/496935 Garnacho-Montero, 2012, Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections, J Antimicrob Chemother., 68, 206, 10.1093/jac/dks347 Grau, 2013, Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain, J Mycol Med, 23, 155, 10.1016/j.mycmed.2013.05.004 Gudlaugsson, 2003, Attributable mortality of nosocomial candidemia, revisited, Clin Infect Dis., 37, 1172, 10.1086/378745 Guillamet, 2015, Development and validation of a clinical prediction rule for candidemia in hospitalized patients with severe sepsis and septic shock, J Crit Care., 30, 715, 10.1016/j.jcrc.2015.03.010 Guinea, 2014, Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain from 2010 to 2011, Antimicrob Agents Chemother., 58, 1529, 10.1128/AAC.02155-13 Hanson, 2012, β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study, PLoS ONE., 7, e42282, 10.1371/journal.pone.0042282 Hermsen, 2011, Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: a matched case-control study, Crit Care., 15, R198, 10.1186/cc10366 Kollef, 2012, Septic shock attributed to Candida infection: importance of empiric therapy and source control, Clin Infect Dis., 54, 1739, 10.1093/cid/cis305 Leon, 2006, A bedside scoring system (Candida score) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization*, Crit Care Med., 34, 730, 10.1097/01.CCM.0000202208.37364.7D León, 2014, What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients, Intensive Care Med., 40, 808, 10.1007/s00134-014-3281-0 León, 2012, Value of ß-D-glucan and Candida albicans germ tube antibody for discriminating between Candida colonization and invasive candidiasis in patients with severe abdominal conditions, Intensive Care Med., 38, 1315, 10.1007/s00134-012-2616-y León, 2009, Usefulness of the Candida score for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study, Crit Care Med., 37, 1624, 10.1097/CCM.0b013e31819daa14 Leroy, 2011, Evaluation of Candida score in critically ill patients: a prospective, multicenter, observational, cohort study, Ann Intensive Care., 1, 50, 10.1186/2110-5820-1-50 Leroy, 2009, Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006), Crit Care Med., 37, 1612, 10.1097/CCM.0b013e31819efac0 Liu, 2013, Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis, Antimicrob Agents Chemother., 57, 1672, 10.1128/AAC.02139-12 Lortholary, 2011, Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients, Antimicrob Agents Chemother., 55, 532, 10.1128/AAC.01128-10 Martínez-Jiménez, 2014, Potential role of Candida albicans germ tube antibody in the diagnosis of deep-seated candidemia, Med Mycol., 72, 270, 10.1093/mmy/myt025 Maseda, 2014, Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration, J Antimicrob Chemother., 69, 1624, 10.1093/jac/dku013 Mora-Duarte, 2002, Comparison of caspofungin and amphotericin B for invasive candidiasis, N Engl J Med., 347, 2020, 10.1056/NEJMoa021585 Mylonakis, 2015, T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial, Clin Infect Dis., 60, 892, 10.1093/cid/ciu959 Ortega, 2010, Candida spp. bloodstream infection: influence of antifungal treatment on outcome, J Antimicrob Chemother., 65, 562, 10.1093/jac/dkp495 Ostrosky-Zeichner, 2011, Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit, Mycoses., 54, 46, 10.1111/j.1439-0507.2009.01756.x Palomar, 2013, Impact of a national multimodal intervention to prevent catheter-related bloodstream infection in the ICU, Crit Care Med., 41, 2364, 10.1097/CCM.0b013e3182923622 Pappas, 2009, Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America, Clin Infect Dis., 48, 503, 10.1086/596757 Pappas, 2003, A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients, Clin Infect Dis., 37, 634, 10.1086/376906 Pemán, 2011, Epidemiology and antifungal susceptibility of bloodstream fungal isolates in pediatric patients: a Spanish multicenter prospective survey, J Clin Microbiol., 49, 4158, 10.1128/JCM.05474-11 Pemán, 2012, Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey, J Antimicrob Chemother., 67, 1181, 10.1093/jac/dks019 Pemán, 2011, Clinical factors associated with a Candida albicans germ tube antibody positive test in intensive care unit patients, BMC Infect Dis., 11, 60, 10.1186/1471-2334-11-60 Pemán, 2012, Hacia el diagnóstico temprano de la candidiasis invasora en el paciente crítico, Rev Iberoam Micol., 29, 71, 10.1016/j.riam.2012.03.002 Pemán, 2012, Combined use of nonculture-based lab techniques in the diagnosis and management of critically ill patients with invasive fungal infections, Expert Rev Anti Infect Ther., 10, 1321, 10.1586/eri.12.128 Pfaller, 2007, Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing, J Clin Microbiol., 45, 1735, 10.1128/JCM.00409-07 Pfaller, 2002, Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000, J Clin Microbiol., 40, 852, 10.1128/JCM.40.3.852-856.2002 Playford, 2009, Assessment of clinical risk predictive rules for invasive candidiasis in a prospective multicentre cohort of ICU patients, Intensive Care Med., 35, 2141, 10.1007/s00134-009-1619-9 Puig-Asensio, 2014, Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain, Clin Microbiol Infect., 20, O245, 10.1111/1469-0691.12380 Puig-Asensio, 2014, Impact of therapeutic strategies on the prognosis of candidemia in the ICU, Crit Care Med., 42, 1423, 10.1097/CCM.0000000000000221 Reboli, 2011, Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients, Pharmacoeconomics., 29, 705, 10.2165/11584810-000000000-00000 Reboli, 2007, Anidulafungin versus fluconazole for invasive candidiasis, N Engl J Med., 356, 2472, 10.1056/NEJMoa066906 Reboli, 2011, Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome, BMC Infect Dis., 11, 261, 10.1186/1471-2334-11-261 Ruhnke, 2012, Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients, Clin Microbiol Infect., 18, 680, 10.1111/j.1469-0691.2012.03784.x Sandven, 2006, Candidemia in Norway (1991 to 2003): results from a nationwide study, J Clin Microbiol., 44, 1977, 10.1128/JCM.00029-06 SEMICYUC. Informes anuales ENVIN-UCI [Internet]. 2014 [citado 9 Jul 2015]. Disponible en: hws.vhebron.net/envin-helics/. Vincent, 2009, International study of the prevalence and outcomes of infection in intensive care units, JAMA., 302, 2323, 10.1001/jama.2009.1754 Weiler, 2013, Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy, Antimicrob Agents Chemother., 57, 4053, 10.1128/AAC.00335-13 Zaragoza, 2014, Development of educational therapeutic recommendations using the DELPHI technique on invasive candidiasis in critically ill adult patients in special situations, Rev Esp Quimioter., 27, 196 Zaragoza, 2013, Épico project. Development of educational recommendations using the DELPHI technique on invasive candidiasis in non-neutropenic critically ill adult patients, Rev Iberoam Micol., 30, 135 Zaragoza, 2009, Clinical significance of the detection of Candida albicans germ tube-specific antibodies in critically ill patients, Clin Microbiol Infect., 15, 592, 10.1111/j.1469-0691.2009.02794.x Zaragoza, 2009, Kinetic patterns of Candida albicans germ tube antibody in critically ill patients: influence on mortality, Clin Vaccine Immunol., 16, 1527, 10.1128/CVI.00183-09 Zaragoza, 2012, Opciones terapéuticas para el tratamiento antifúngico en el paciente crítico, Rev Iberoam Micol., 29, 108, 10.1016/j.riam.2012.03.009 Zaragoza, 2012, Micosis invasoras en el paciente crítico, Rev Iberoam Micol., 29, 69, 10.1016/j.riam.2012.03.001